Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharm (NQ: LGND )

71.00 -4.31 (-5.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 90,586
Open 74.78
Bid (Size) 70.50 (1)
Ask (Size) 74.85 (1)
Prev. Close 75.31
Today's Range 70.41 - 74.78
52wk Range 57.77 - 109.00
Shares Outstanding 16,676,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Stocks That Smart Investors Should Be Flocking to Now
Investors may want to detour away from the obvious trades and consider compelling top stocks for smart investors. 
Via InvestorPlace
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in  
Via Benzinga

Performance

YTD
+7.53%
+7.53%
1 Month
-10.50%
-10.50%
3 Month
-0.73%
-0.73%
6 Month
+1.87%
+1.87%
1 Year
-14.27%
-14.27%

More News

Read More
Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Recap: Ligand Pharmaceuticals Q1 Earnings
Via Benzinga
Ligand Pharmaceuticals Earnings Preview
Via Benzinga
Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Ligand Reports First Quarter 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
Via Benzinga
Earnings Scheduled For February 22, 2023
Via Benzinga
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report Fourth Quarter Financial Results on February 22
From Ligand Pharmaceuticals Incorporated
Via Business Wire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Via Benzinga
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tesla To $175? Here Are 10 Other Price Target Changes For Friday
Via Benzinga
Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says
Via Benzinga
Ligand Pharma Issues Mixed Guidance For FY23
Via Benzinga
Ligand Provides Highlights from its Investor and Analyst Day Event
From Ligand Pharmaceuticals
Via Business Wire
Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Hold Investor and Analyst Day on December 13
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Reports Third Quarter 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Earnings Outlook For Ligand Pharmaceuticals
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.